Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

Needham analyst Michael Matson has maintained their neutral stance on RMD stock, giving a Hold rating on January 29.Invest with Confidence: ...

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing ...

The quarter saw ResMed continue its strategic expansion with significant investments in innovation, including the launch of new products like the AirTouch N30i mask, designed to enhance patient ...

ResMed Earnings: Solid Result With Strong Mask Sales and Gross Margin Expansion Shares in narrow-moat ResMed remain undervalued following a solid fourth-quarter fiscal 2024. Underlying EBIT of USD ...